Oh Dong Y, Son Minkook, Ko Seung M, Jang Ye J, Kim Kwang H, Kim Kwang J, Park Eun J
From the Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.
Department of Physiology, College of Medicine, Dong-A University, Busan, Republic of Korea.
Indian J Dermatol. 2025 Sep-Oct;70(5):240-245. doi: 10.4103/ijd.ijd_1134_23. Epub 2025 Sep 1.
Several studies have reported the association between statin use and skin cancer; however, the results have been conflicting. Furthermore, no large-scale studies have reported the relationship between statin exposure and skin cancer in Asian countries.
The aim of this study was to investigate the association between statin exposure and skin cancer in Korea.
This nationwide population-based case-control study used data from the National Health Insurance Service database between 2007 and 2018. We enrolled 109,327 patients in the skin cancer group and extracted 109,327 controls using 1:1 propensity score matching. Data on statin exposure within 5 years were collected, and multivariable-adjusted conditional logistic regression analysis was performed.
Statin exposure was present in 29.6% of patients in the skin cancer group and 22.3% of patients in the control group, with a statistically significant difference between the two groups. The adjusted odds ratio (OR) (95% confidence interval [CI]) for the association between statin exposure and skin cancer was 1.71 (1.67-1.75). All types of statins, especially lipophilic statins (adjusted OR, 1.58; 95% CI, 1.54-1.62), were associated with skin cancer. However, the association with skin cancer was not statistically significantly different between lipophilic and hydrophilic statins. Subgroup analyses according to age, sex and comorbidity showed a significant association between statin exposure and skin cancer, regardless of subgroup.
Our study revealed an association between statin exposure and skin cancer in Korea.
多项研究报告了他汀类药物使用与皮肤癌之间的关联;然而,结果相互矛盾。此外,尚无大规模研究报告亚洲国家他汀类药物暴露与皮肤癌之间的关系。
本研究旨在调查韩国他汀类药物暴露与皮肤癌之间的关联。
这项基于全国人群的病例对照研究使用了2007年至2018年期间国民健康保险服务数据库的数据。我们纳入了109327例皮肤癌组患者,并通过1:1倾向评分匹配提取了109327例对照。收集了5年内他汀类药物暴露的数据,并进行了多变量调整的条件逻辑回归分析。
皮肤癌组29.6%的患者有他汀类药物暴露,对照组为22.3%,两组之间存在统计学显著差异。他汀类药物暴露与皮肤癌关联的调整比值比(OR)(95%置信区间[CI])为1.71(1.67 - 1.75)。所有类型的他汀类药物,尤其是亲脂性他汀类药物(调整后OR,1.58;95%CI,1.54 - 1.62),均与皮肤癌相关。然而,亲脂性他汀类药物与亲水性他汀类药物在与皮肤癌的关联上无统计学显著差异。根据年龄、性别和合并症进行的亚组分析显示,无论亚组如何,他汀类药物暴露与皮肤癌之间均存在显著关联。
我们的研究揭示了韩国他汀类药物暴露与皮肤癌之间的关联。